Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial

• Published in: The Lancet regional health. Western Pacific Vol. 39; p. 100847
• Main Authors: Mori, Masaaki, Yoshizaki, Kanako, Watabe, Shinichi, Ishige, Mika, Hinoki, Akinari, Kondo, Takuya, Taguchi, Tomoaki, Hasegawa, Hisaya, Hatata, Tomoko, Tanuma, Naoyuki, Kirino, Kosuke, Hirakawa, Akihiro, Naruto, Takuya, Imai, Minoru, Koike, Ryuji, Hosoi, Kenichiro, Kusuda, Satoshi
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2023; Elsevier
• Subjects: Airway stenosis; Congenital esophageal atresia; Efficacy; Inherited metabolic disease; Neuromuscular disease; Palivizumab; Pediatric patient; Pulmonary hypoplasia; Respiratory syncytial virus infection; Inherited metabolic disease; Palivizumab; Respiratory syncytial virus infection; Neuromuscular disease; Pulmonary hypoplasia; Efficacy; Pediatric patient; Airway stenosis; Congenital esophageal atresia
• ISSN: 2666-6065; 2666-6065
• DOI: 10.1016/j.lanwpc.2023.100847

Pediatric patients with certain rare diseases are at increased risk of severe respiratory syncytial virus (RSV) infection. However, the prophylactic use of anti-RSV antibody (palivizumab) in these patients is not indicated at present in Japan. This first-in-the-world multicenter, uncontrolled, open-label, phase II clinical trial was carried out between 28 July 2019 and 24 September 2021 at seven medical institutions in Japan to investigate the efficacy, safety, and pharmacokinetics of palivizumab in 23 subjects recruited from among neonates, infants, or children aged 24 months or younger who had any of the following conditions: pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, inherited metabolic disease, or neuromuscular disease. At least four continuous doses of palivizumab were administered intramuscularly at 15 mg/kg at intervals of 30 days. Twenty-three enrolled subjects completed the study. No subject required hospitalization for RSV. Adverse events (AE) did not notably differ from the event terms described in the latest interview form. Five severe AEs required unplanned hospitalization, but resolved without RSV infection. Therapeutically effective concentrations of palivizumab were maintained throughout the study period. Palivizumab might be well tolerated and effective in preventing serious respiratory symptoms and hospitalization due to severe RSV infection, indicating the prophylactic use in the pediatric patients included in this study. Japan Agency for Medical Research and Development (AMED), grant numbers 19lk0201097h0001 (to MM), 20lk0201097h0002 (to MM), 21lk0201097h0003 (to MM), and 22lk0201097h0004 (to MM). AMED did not have any role in the execution of this study, analysis and interpretation of the data, or the decision to submit the results.